docetaxel anhydrous has been researched along with formononetin in 1 studies
| Studies (docetaxel anhydrous) | Trials (docetaxel anhydrous) | Recent Studies (post-2010) (docetaxel anhydrous) | Studies (formononetin) | Trials (formononetin) | Recent Studies (post-2010) (formononetin) |
|---|---|---|---|---|---|
| 12,110 | 3,216 | 6,920 | 483 | 10 | 314 |
| Protein | Taxonomy | docetaxel anhydrous (IC50) | formononetin (IC50) |
|---|---|---|---|
| Neuraminidase | Influenza A virus (A/Wilson-Smith/1933(H1N1)) | 3.6225 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dong, Z; Guo, J; Pan, W; Tian, C; Wang, H; Wang, Y; Yan, J | 1 |
1 other study(ies) available for docetaxel anhydrous and formononetin
| Article | Year |
|---|---|
Prostate Cancer Therapy Using Docetaxel and Formononetin Combination: Hyaluronic Acid and Epidermal Growth Factor Receptor Targeted Peptide Dual Ligands Modified Binary Nanoparticles to Facilitate the in vivo Anti-Tumor Activity.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Docetaxel; Drug Carriers; ErbB Receptors; Humans; Hyaluronic Acid; Isoflavones; Ligands; Male; Mice; Nanoparticles; Peptides; Prostate; Prostatic Neoplasms; Taxoids | 2022 |